Favourable Prognosis Value of Matrix Metalloproteinase-10 Overexpression in Urinary Bladder Cancer
Cancer Biology Unit, King Fahd Medical Research Center, King Abdulaziz University, 1King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, 2Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 22252, Saudi Arabia, 3Department of Molecular Genetics and Enzymology, Human Genetics and Genome Research Institute, National Research Centre, Cairo 12622, Egypt, 4Center of Excellence in Genomic Medicine Research, 5Department of Pathology, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah 22252, 6Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Jeddah 21499, Saudi Arabia, 7Cell Biology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo 12622, Egypt
M. M. Mahmoud, Cancer Biology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia, E-mail: email@example.com
Matrix metalloproteinase-10 is an extracellular matrix degradation enzyme that facilitates cell invasion in many cancers and is associated with poor clinical outcomes. In urinary bladder cancer, the clinical importance of matrix metalloproteinase-10 remains inadequately explored and poorly related to the patients clinicopathological factors and survival status. Hence, this study was conducted to explore matrix metalloproteinase-10 prognostic value in bladder cancer using a cohort of patients in Saudi Arabia. A total of 170 primary transitional cell carcinoma tissue sections of consent patients were prepared and arranged as tissue microarray, and the expression of matrix metalloproteinase-10 was analysed by immunohistochemistry. The potential clinical value of matrix metalloproteinase-10 was assessed by a correlation analysis of its expression with the patient’s clinicopathological features. The present data revealed that moderate (+2) and high (+3) matrix metalloproteinase-10 expression was detected in 47 % of our bladder cancer patient’s cohort. The expression was strongly associated with low-grade non-invasive tumours. The analysis also displayed a significant positive association of matrix metalloproteinase-10 expression with better overall survival and a low recurrence rate (p=0.023). The study showed an association of matrix metalloproteinase-10 expression with less invasive tumorigenic profiles and a better overall survival rate. This finding may suggest matrix metalloproteinase-10 as a biomarker for favourable treatment response. Further prospective investigations are needed to profoundly evaluate matrix metalloproteinase-10 functional role in bladder cancer.